Loading cancer entity…
Loading cancer entity…
Clinical trials
195 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (19)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05472948 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT01781728 | Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy | terminated | Phase 2 | 56 | Washington University School of MedicineOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04491955 | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01208103 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00621036 | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00003522 | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine | terminated | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00433550 | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer | completed | Phase 2 | 33 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00753675 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer(VANGOGH) | completed | Phase 2 | 174 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00660699 | A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00589563 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | completed | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00410462 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | unknown | Phase 2 | 118 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Aug 8, 2014 | clinicaltrials |
| NCT00005874 | Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | completed | Phase 2 | — | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00025441 | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors | completed | Phase 2 | — | Societe Internationale d'Oncologie PediatriqueOTHER | 3 | Dec 4, 2013 | clinicaltrials |
| NCT00669812 | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma | unknown | Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00026468 | Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis | withdrawn | Phase 2 / Phase 3 | 0 | University of UtahOTHER | 0 | Jul 24, 2013 | clinicaltrials |
| NCT00006039 | Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00012246 | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | terminated | Phase 2 | 7 | The University of Texas Medical Branch, GalvestonOTHER | 1 | May 16, 2013 | clinicaltrials |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00004066 | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | completed | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials